Endo International (ENDP) announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck’s (MRK) Noxafil in the U.S., following final approval from the U.S. FDA of its Abbreviated New Drug Application. According to IQVIA, Noxafil vial sales were approximately $25M for the 12 months ended May 31, 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Kineta to Receive $5M milestone payment from Merck
- SCHD ETF: Technical Indicators Signal a “Buy”
- Merck announces topline results from the Phase 3 KEYNOTE-585 trial
- Bristol-Myers sues, calls Inflation Reduction Act provisions ‘unconstitutional’
- Bristol Myers Squibb (NYSE:BMY) Joins Quest to Prevent Fed’s Price Negotiations